Dermal Fillers Market: Trends, Applications & What’s Ahead

The modern filler market is no longer simply about adding volume to lips or softening smile lines. Today’s products can be selected for cheek structure, chin projection, jawline definition, temples, under-eye hollowing, skin smoothness, hands, facial folds and other product-specific indications. At the same time, collagen stimulators such as poly-L-lactic acid and calcium hydroxylapatite are increasingly discussed alongside traditional hyaluronic acid fillers even though they behave differently.

How Large Is the Dermal Filler Market?

There is no single authoritative dollar figure for the worldwide dermal filler market.

Commercial research firms publish market-size forecasts, but their estimates vary because some count only hyaluronic acid products while others include calcium hydroxylapatite, poly-L-lactic acid, PMMA, biostimulators, distribution revenue or other injectable categories.

For that reason, procedure data from professional societies can provide a more transparent picture of actual treatment demand.

The American Society of Plastic Surgeons ranked soft-tissue and hyaluronic acid fillers as the second most-requested minimally invasive treatment category in 2025, behind neuromodulators. Fillers represented 30% of minimally invasive treatments in its dataset.

ASPS reported that approximately 70% of filler treatments focused on facial rejuvenation, while lip augmentation represented approximately 23%.

Because ASPS changed the way it reports minimally invasive data in 2025, it did not publish an estimated national procedure count for fillers. Comparing percentages with older ASPS procedure totals as if they came from the same methodology would therefore be misleading.

What Does the Global Data Show?

The latest completed ISAPS Global Survey provides a broader international view.

Hyaluronic acid therefore remains substantially larger by procedure volume, but the numbers show why collagen-stimulating injectables have become an important part of the broader aesthetics conversation.

ISAPS has completed collection for its 2025 global survey, but as of September 2026 those results are still being analyzed. The 2024 report remains the most recent published global procedure dataset.

Not Every Injectable Filler Works the Same Way

The term “filler” is often used broadly, but modern injectable products fall into several materially different categories.

The distinction matters because these products differ in onset, reversibility, longevity, injection depth, treatment planning and risk management.

Hyaluronic acid fillers can often be reduced with hyaluronidase when clinically appropriate. That is not true of every injectable material. Permanent or collagen-stimulating products should not be discussed as though they can simply be dissolved like an HA gel.

Trend 1: Product Selection Is Becoming More Anatomy-Specific

One of the clearest changes in the filler market is the expansion of products and indications for specific facial regions.

Historically, patients often asked simply for “a syringe of filler.” Today, FDA-approved products may be specifically studied for lips, cheeks, chin, jawline, temples, under-eye hollows, skin folds, hands or skin quality.

Recent examples show how quickly this is evolving.

Restylane Contour received an expanded FDA indication in March 2026 for correction of temple hollowing in adults over 21.

Juvéderm Voluma XC already carries an FDA-approved indication for temple augmentation, in addition to other product-specific indications.

Juvéderm Volux XC is specifically approved for improvement of jawline definition.

Restylane Eyelight and Juvéderm Volbella XC have FDA-approved indications involving under-eye hollowing.

The direction is clear: the industry is moving away from thinking of filler as one generic substance placed throughout the face.

For patients comparing two of the largest HA families, see Juvéderm vs. Restylane.

Trend 2: Skin Quality Is Becoming Part of the Injectable Market

Traditional dermal fillers were largely associated with replacing volume or creating structure. Newer indications increasingly blur the line between structural filling and skin-quality treatment.

SKINVIVE by Juvéderm was initially FDA-approved for intradermal injection to improve cheek skin smoothness. In June 2026, its indication expanded to include intradermal and/or subdermal injection to reduce neck lines for improvement of neck appearance in adults over 21.

This is different from using a firm structural filler to project a chin or jawline. It reflects a broader injectable category in which product depth, rheology and biological purpose are becoming more specialized.

That does not mean filler is replacing lasers, microneedling or energy-based skin treatments. Pigmentation, acne scarring, vascular redness, significant laxity and many texture concerns may still be better addressed with a different modality.

Trend 3: Biostimulators Are Growing Alongside HA Fillers

Another important market shift is growing interest in products that stimulate the patient’s own collagen rather than simply providing immediate gel volume.

ISAPS estimated 642,566 poly-L-lactic acid procedures in 2024. Compared with its 2020 estimate, that represents an increase of more than fivefold, although ISAPS did not provide a comparable 2023 figure for this category.

Calcium hydroxylapatite procedures reached 418,173 in 2024, up 13.7% year over year.

Manufacturer data point in the same general direction, although company financial results should not be confused with total market statistics. Galderma reported that its Fillers & Biostimulators business generated $611 million in first-half 2026 net sales, up 10.5% at constant currency, even while the company described the broader filler market as soft.

That combination is revealing. Traditional filler demand does not need to rise at the same rate every year for the injectable market to continue evolving.

Trend 4: “More Filler” Is Giving Way to More Selective Planning

The clinical trend is also changing.

A whole-face assessment does not mean injecting the whole face. In many patients, the best result comes from identifying one structural relationship that matters rather than adding volume to every area that shows age-related change.

A lip concern may partly reflect chin projection. A poorly defined jawline may reflect tissue descent rather than inadequate filler. A tired midface may involve volume loss, but it may also involve skin quality, tear-trough anatomy or laxity.

This is why modern filler planning increasingly focuses on anatomy, tissue depth, movement and proportion instead of simply counting syringes.

The same principle is discussed in our guide to choosing an injectables provider.

Where Are Dermal Fillers Used?

FDA-approved uses vary by product. Depending on the specific filler, approved applications can include:

• lip augmentation
• cheek and midface volume restoration
• chin augmentation
• jawline definition
• temple hollowing
• under-eye hollowing
• nasolabial folds and other facial wrinkles
• perioral lines
• back-of-hand volume restoration
• selected acne scars
• cheek skin smoothness
• neck-line improvement with specifically approved products

Not every filler is approved for every one of these uses.

The FDA reviews each product and indication separately. Patients should therefore know the exact product being injected, not merely that they are receiving “filler.”

What About Liquid Rhinoplasty and Other Off-Label Uses?

Some widely discussed filler treatments remain off-label.

The FDA does not broadly approve dermal filler injection into every facial region. Product labeling and approved indications should be checked individually, especially for higher-risk areas.

The nose is a common example. Injectable rhinoplasty is performed by some experienced clinicians, but nasal filler use is off-label in the United States and involves vascular anatomy that can create serious complications.

Off-label treatment is not automatically inappropriate medicine, but it should be disclosed honestly rather than marketed as though FDA approval applies to the area.

Safety Is One of the Most Important Market Trends

As filler availability expands, the safety conversation becomes more important.

The FDA describes accidental injection into a blood vessel as the most serious dermal filler complication. Vascular occlusion can interrupt blood supply and lead to skin necrosis, visual abnormalities including blindness, stroke and, in rare cases, death.

Other possible complications include swelling, bruising, tenderness, infection, nodules, granulomas, inflammatory reactions and migration.

The FDA also warns consumers against buying injectable filler directly online and against needle-free filler devices. FDA-approved dermal fillers are prescription medical devices intended to be administered by licensed health care professionals.

Which Brands Are Shaping the U.S. Market?

The U.S. market includes several established product families rather than one dominant type of filler.

Skin Works carries multiple filler and biostimulator families so product selection can follow anatomy rather than requiring every patient to fit one manufacturer’s portfolio. The current local menu is available on our dermal fillers page.

What Is Ahead for the Dermal Filler Market?

More indication-specific products

Recent approvals for temples, under-eyes, jawline, cheek skin smoothness and neck lines suggest that the market will continue moving toward products studied for narrower anatomical roles rather than one gel being marketed for the entire face.

More distinction between volume and skin quality

Injectables are expanding beyond simple volumization. The SKINVIVE approvals are one example of a product intended for intradermal treatment and skin smoothness rather than primarily projecting facial structure.

Continued growth in biostimulation

PLLA and calcium hydroxylapatite procedure data suggest that demand for collagen-stimulating approaches is becoming a larger part of the injectable market.

More emphasis on product physics

Providers increasingly select HA fillers based on characteristics such as elasticity, cohesivity, flexibility, tissue depth and movement rather than assuming that all products within one brand behave the same way.

Greater scrutiny of training and complication management

As more clinics enter aesthetic medicine, product authenticity, provider licensing, anatomy training and emergency protocols become increasingly important differentiators.

Less useful emphasis on speculative market forecasts

Commercial forecasts can be helpful for investors, but they are less useful to patients than procedure demand, regulatory approvals and real-world clinical developments. Forecasts also change substantially depending on what each research company includes in its definition of the filler market.

Frequently Asked Questions